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A multicentre study evaluated the efficacy and safety of darbepoetin alpha administered weekly (QW), every 3 weeks (Q3W), and
every 4 weeks (Q4W) to anaemic patients with cancer not concurrently receiving chemotherapy or radiotherapy. The QW portion
(n¼102) was an open-label, sequential, dose-escalation design; cohorts received darbepoetin alpha QW by subcutaneous (s.c.)
injection at 0.5, 1.0, 2.25, or 4.5mgkg
 1 week
 1 for 12 weeks. The 12-week placebo-controlled, double–blind Q3W (6.75mgkg
 1)
and Q4W (6.75 or 10.0mgkg
 1) schedules (n¼86), which enrolled different patients, took place after the QW schedule and were
followed by a 12-week, open-label phase. Patients were evaluated for change in haemoglobin end points and red blood cell
transfusions, serum darbepoetin alpha concentration, and safety. Selected domains of health-related quality of life (HRQOL) were
measured. With QW dosing, at least 70% of each cohort had a haemoglobin increase from baseline of X2gdl
 1 or a concentration
X12gdl
 1 (haematopoietic response). In the 4.5mgkg
 1 QW cohort, all patients achieved a haematopoietic response (100%; 95%
confidence interval (CI)¼100, 100). In the Q3W and Q4W schedules, all cohorts had at least 60% of patients who achieved
a haematopoietic response. Darbepoetin alpha effectively increases haemoglobin concentration when given QW, Q3W, or Q4W.
Less-frequent administration may benefit patients with chronic anaemia of cancer and their caregivers alike.
British Journal of Cancer (2003) 88, 1851–1858. doi:10.1038/sj.bjc.6600994 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: anaemia; chronic disease; darbepoetin alpha; erythropoietin
                                                    
Patients with cancer commonly develop anaemia, even if they are
not receiving chemotherapy or radiotherapy. Anaemia in these
patients may be the result of blood loss, haemolysis, bone marrow
malfunction because of invasion with tumour, or other factors.
Frequently, however, the cause is the anaemia of chronic disease
(Cartwright, 1966; Lee, 1983). Patients with anaemia of chronic
disease have a shortened red blood cell survival for which
erythropoiesis fails to compensate (Miller et al, 1990; Koeller,
1998); experimental evidence indicates that inflammatory cyto-
kines are responsible for the disruption of normal erythropoiesis
(Means et al, 1995; Jelkmann, 1988). This occurs through several
characteristic mechanisms. Iron utilisation appears defective, as
indicated by typically low serum iron in the presence of adequate
or elevated iron stores (Lee, 1983; Means and Kranz, 1992;
Moliterno and Spivak, 1996). In addition, bone marrow erythroid
progenitor cells show a blunted response to erythropoietin, with
insufficient proliferation and a low circulating reticulocyte count
(Means and Kranz, 1992; Moliterno and Spivak, 1996; Nowrousian,
1998). Finally, the production of erythropoietin itself in response
to anaemia is inadequate. Compared to patients without cancer
who have iron-deficiency anaemia, anaemic cancer patients have a
smaller increase in erythropoietin for their level of anaemia
(Ozguroglu et al, 2000).
Although anaemia of chronic disease is often mild to moderate
in severity, this degree of anaemia and the associated symptoms
can have considerably adverse effects on the lives of patients
already in poor health. Fatigue, dyspnoea, and weakness have been
shown to significantly affect the quality of daily life in patients
with cancer (Cella, 1997a; Vogelzang et al, 1997; Curt, 2000).
Studies in patients who have low haemoglobin levels for extended
periods due to chronic renal insufficiency point to untreated
anaemia as an independent risk factor for cardiovascular disease
(Foley et al, 1996). Treatment with recombinant human erythro-
poietin (rHuEPO) earlier in the course of renal failure and
correction of haemoglobin to higher levels are topics of current
debate and investigation within the renal disease community, as
some evidence suggests this approach may prevent the develop-
ment or worsening of cardiac damage including left ventricular
hypertrophy (NKF Anemia Work Group, 1997; Obrador et al, 1999;
Hayashi et al, 2000; Macdougall, 2000).
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lAn initial study in patients with cancer who were not receiving
chemotherapy indicated that rHuEPO can correct anaemia in this
population as well, with 32% of patients achieving a haematocrit
increase of X6% when rHuEPO was given at 100Ukg
 1 three
times weekly for 8 weeks (Abels et al, 1991). A significant
reduction in red blood cell transfusions was not achieved at this
dose and schedule; however, in a subsequent study using a higher
dose of rHuEPO and longer duration of administration (150Ukg
 1
three times weekly for up to 12 weeks) (Quirt et al, 2001), the
percentage of nonchemotherapy patients requiring transfusions
was significantly decreased by the second month of treatment.
In the latter study, 48% of patients (39% of whom required a
doubling of dose at week 5) met the definition for haemoglobin
response (an increase in haemoglobin of at least 2gdl
 1 without
transfusion).
Darbepoetin alpha is a protein that stimulates erythropoiesis in
the same manner as rHuEPO, but has an increased number of
sialic acid residues. The sialic acid-containing carbohydrate of
erythropoietin determines its serum half-life (Egrie et al, 1993),
and darbepoetin alpha has demonstrated a two- to three-fold
longer serum half-life than rHuEPO in animal models and in
patients with chronic renal failure (MacDougall et al, 1999; Egrie
and Browne, 2001). In cancer patients undergoing chemotherapy,
darbepoetin alpha therapy increased haemoglobin concentration
when administered weekly (QW), or every 2 (Q2W), 3 (Q3W), or 4
(Q4W) weeks (Hedenus et al, 2002; Kotasek et al, 2002; Glaspy et al,
2002).
The study described here was the first to evaluate the dose,
schedule, and pharmacokinetic profile of darbepoetin alpha
in patients with anaemia of cancer, a condition for which
dosing at weekly intervals or greater would be valuable.
Darbepoetin alpha was given at one of four QW doses (from 0.5
to 4.5mgkg
 1); at 6.75mgkg
 1 Q3W; and at 6.75 or 10.0mgkg
 1
Q4W.
MATERIALS AND METHODS
Study population
The institutional review boards for each of the 24 participating
centres in the US approved the protocol and all patients provided
written informed consent before any study-specific procedures
were done. Men or women who were X18 years of age with
nonmyeloid malignancies were eligible for this study if they had
anaemia (haemoglobin concentration p11.0gdl
 1) due to either
cancer or previous chemotherapy or radiotherapy (patients were
required to have serum folate X2.0ngml
 1 and vitamin B12
X200pgml
 1, no haemolysis, and no gastrointestinal bleeding).
Patients were not currently receiving chemotherapy or radio-
therapy or planning to receive any for at least 16 weeks. A X3-
month life expectancy was required, as were an Eastern
Cooperative Oncology Group (ECOG) performance status of 0–2,
adequate renal function (serum creatinine concentration
p176.8mmoll
 1) and liver function (serum bilirubin p1.5 times
the central laboratory upper limit of normal), and a platelet count
of X50 10
9l
 1. Iron therapy and red blood cell transfusion
policies were left to the discretion of the investigators, although
transfusions were recommended at a haemoglobin level of
p8.0gdl
 1.
Patients were excluded from the study if they had both
transferrin saturation o15% and ferritin o10ngml
 1; had
significant central nervous system, cardiac, or inflammatory
diseases; or had known primary haematologic disorders that could
cause anaemia. Patients were also excluded if they had received
chemotherapy or rHuEPO within 8 weeks before enrolment, any
red blood cell transfusion within 16 days of enrolment, or 42 red
blood cell transfusions within 4 weeks of enrolment.
Study design
This was a multicentre, dose- and schedule-finding study in
patients with nonmyeloid tumours who were not currently
receiving chemotherapy. Three schedules were evaluated; darbe-
poetin alpha administered QW, Q3W, and Q4W. Different patients
were enrolled in each schedule. In the QW schedule, patients had
12 weeks of open-label therapy with darbepoetin alpha given
subcutaneously (s.c.) once weekly at sequentially escalated doses of
0.5, 1.0, 2.25, or 4.5mgkg
 1. The Q3W and Q4W schedules took
place after the completion of the QW schedule, and were double-
blind and placebo-controlled. Patients were randomised in a 3:1
ratio to receive darbepoetin alpha (6.75mgkg
 1 Q3W, 6.75mgkg
 1
Q4W or 10.0mgkg
 1 Q4W) or placebo (Q3W or Q4W) S.C. for
the first 12 weeks (blinded treatment phase), and could then
participate in an optional, 12-week, open-label darbepoetin alpha
treatment phase with a 4-week observation period after the last
dose. Placebo patients were assigned the dose of darbepoetin alpha
for which they served as the control during the blinded phase.
No dose increase for inadequate response was allowed in this
study. Study drug was to be withheld if a patient’s haemoglobin
value increased to 415.0gdl
 1 for men or 414.0gdl
 1 for
women. Once the haemoglobin value was p13.0gdl
 1, study drug
could be reinstated at a lower dose. Initially in the QW schedule,
an increase in haemoglobin concentration of X2.0gdl
 1 in the
absence of a red blood cell transfusion during the previous 28 days
was used as a criterion for dose reductions. This criterion was
amended to add the requirement that the haemoglobin concentra-
tion also be 413.0gdl
 1. If the dose was reduced, the patient
remained at that dose until the end of the 12-week treatment
period.
Predose and 48-h postdose serum samples for determination of
darbepoetin alpha concentration were collected in a subset of
patients at weeks 1, 4, and 12 (QW); 1, 7, and 13 (Q3W); and 1, 5,
and 13 (Q4W).
Study drug
Darbepoetin alpha (Aranesp
s, Amgen Inc., Thousand Oaks, CA,
USA) was supplied in vials as a clear, colourless, sterile protein
containing 100, 300, 500, 1000, or 1500mg darbepoetin alpha
per ml. Placebo was supplied in identical vials.
Study endpoints
All three schedules evaluated the potential efficacy of darbepoetin
alpha. Efficacy was assessed as the incidence of patients achieving
haematopoietic response, defined as an increase in haemoglobin of
X2.0gdl
 1 from baseline during the 12-week treatment period, or
a haemoglobin concentration X12.0gdl
 1, in the absence of any
red blood cell transfusions during the previous 28 days. This end
point is a commonly used measurement of response in other
reports in the literature (Demetri et al, 1998; Gabrilove et al, 2001).
Other haemoglobin end points were the time to haematopoietic
response, the incidence of patients achieving a haemoglobin
response (an increase in haemoglobin concentration of X2.0gdl
 1
from baseline during the 12-week treatment period, in the absence
of any red blood cell transfusions during the previous 28 days),
and the change in haemoglobin from baseline during treatment.
The incidence of red blood cell transfusions was assessed using a
subset of the analysis set. In other studies evaluating red blood cell
transfusion requirements (Abels, 1992; Dammacco et al, 2001;
Littlewood et al, 2001), treatment effects were not observed until
after 4 weeks of treatment. Therefore, the incidence of transfusions
was analysed from week 5 to the end of the treatment period.
Serum darbepoetin alpha concentration was determined in a
subset of patients.
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incidence of adverse events by dose and treatment group, and by
evaluating the formation of antibodies resulting from darbepoetin
alpha administration. A radioimmunoprecipitation screening
assay was used to detect seroreactivity to darbepoetin alpha, and
a cell-based bioassay to detect neutralising or inhibiting effects on
the activity of darbepoetin alpha.
The primary health-related quality-of-life (HRQOL) scale in this
study was the FACT-Fatigue subscale score, which has been
validated with oncology patients (Cella, 1997a). Patients completed
the HRQOL questionnaire (Cella, 1997b), which included the
FACT-An (anaemia/fatigue) scales (FACT-General scales and the
FACT-Fatigue subscale), every 4 weeks before any other study
procedures.
Statistical analysis
Except for red blood cell transfusions, statistical analyses were
carried out on the set of patients who received at least one dose of
study drug. Patients who had more than one transfusion were
counted only once in calculating the incidence of transfusions.
Baseline demographic and clinical characteristics were sum-
marised by using the mean and standard deviation (s.d.) for
continuous measures and the number and percent for categorical
measures. The number and proportion of patients in each dose
group were calculated for haematopoietic response, haemoglobin
response, and incidence of transfusions from week 5 to the end of
the treatment period (week 12 in the QW schedule, week 12 of the
blinded phase in the Q3W/Q4W schedules). The proportion was
estimated by taking 1 minus the Kaplan-Meier (K-M) estimate of
the survivor function at the time of the last observed endpoint (the
K-M estimate). Approximate 95% confidence intervals (CIs) for
the K-M estimate were calculated using Greenwood’s (Kalbfleisch
and Prentice, 1980) estimate of the variance and assuming a
normal distribution of the survivor function.
Time to haematopoietic response was calculated as the time from
study day 1 to the first occurrence of the relevant haemoglobin end
point.
The change in haemoglobin concentration (mean and standard
error (s.e.)) was assessed by (1) subtracting the baseline
haemoglobin value from the end-of-treatment-phase value for
each patient (all patients had an observed or imputed value for this
analysis), (2) using the set of patients who completed at least
12 weeks of treatment, and (3) for the Q3W and Q4W schedules,
as the end of the open-label phase value minus the beginning
of the open-label phase value for each patient. If a patient had a
transfusion within 28 days before the last treatment phase
haemoglobin value, the last pretransfusion haemoglobin value
was substituted to discount the effect of the transfusion on
haemoglobin concentration.
The number (%) of patients experiencing adverse events and
the number (%) of patients with antibodies resulting from
darbepoetin alpha administration were tabulated. The pharmaco-
kinetic analysis was performed using noncompartmental methods.
RESULTS
Patient demographics and disposition
A total of 102 patients in the QW schedule and 86 patients in the
Q3W/Q4W schedules (64 darbepoetin alpha and 22 placebo)
received at least one dose of study drug (Figure 1). Only six
patients were enrolled into the 0.5mgkg
 1 cohort of the QW
schedule (the total number on study at the time the Data
Monitoring Committee recommended escalation to the next dose
cohort as the specified safety criteria were met).
Baseline demographic and clinical characteristics of patients
were generally well balanced between the cohorts including the
placebo cohort (Table 1). The most frequent diagnosis was breast
cancer, but a large proportion of patients with other malignancies
(e.g., lung, gastrointestinal, gynaecologic, genitourinary) were also
represented. The 6.75mgkg
 1 Q3W cohort had a greater propor-
tion of women and a higher median endogenous erythropoietin
concentration at baseline compared with the other cohorts. A total
of 156 (83%) patients had received prior chemotherapy or
radiotherapy; of these, 112 (72%) had undergone their last
chemotherapy or radiotherapy at least 6 months previously. All
patients had undergone their last chemotherapy at least 8 weeks
previously and were therefore eligible for the study. At least 80% of
patients in each treatment group had an ECOG status of o2.
The disposition of patients enrolled into the trial is given in
Figure 1. A total of 77 patients (73%) completed the QW schedule,
while 43 (67%) patients receiving darbepoetin alpha and 16 (73%)
patients receiving placebo completed the blinded portion of the
Q3W/Q4W schedules. As expected in this population, death,
disease progression, and/or intervention with chemotherapy or
radiotherapy were frequent reasons for withdrawal from study.
Fifty-nine patients enrolled into the open-label extension of the
Q3W/Q4W schedules and received darbepoetin alpha. Six (6%)
patients died during the QW schedule of the study, and five (5%)
died during the Q3W/Q4W schedules (three during the blinded
phase and two during the open-label phase). None of these deaths
were considered related to study drug treatment.
QW schedule
Screened = 186
Enrolled = 105
Received study drug = 102
  Death = 6 (6%)
  Disease progression = 4 (4%)
  Adverse event = 3 (3%)
  Lost to follow-up = 1 (1%)
  Consent withdrawn = 5 (5%)
  Protocol violation = 3 (3%)
  Began chemotherapy = 2 (2%)
  Noncompliance = 2 (2%)
  Ineligibility determined = 2 (2%)
Discontinued:
Completed study = 77 (73%)
Q3W/Q4W schedules
Screened = 131
Randomised = 86
Received study 
drug = 22 placebo
Received study drug
= 64 darbepoetin alpha
  Disease progression = 2 (9%)
  Adverse event = 1 (5%)
  Consent withdrawn = 2 (9%)
  Administrative decision = 1 (5%)
Discontinued:
  Death = 3 (5%)
  Disease progression = 5 (8%)
  Adverse event = 2 (3%)
  Consent withdrawn = 9 (14%)
  Protocol violation = 1 (2%)
  Other = 1 (2%)
Discontinued:
Completed blinded phase = 43 (67%) Completed blinded phase = 16 (73%)
Figure 1 Disposition of patients.
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lTable 1 Baseline demographic and clinical characteristics: (a) QW schedule, (b) Q3W and Q4W schedules
(A) Darbepoetin alpha dose (lgkg
 1 QW) (B) Treatment group – placebo or darbepoetin alpha
0.5
(N¼6)
1.0
(N¼33)
2.25
(N¼33)
4.5
(N¼30)
Placebo
(N¼22)
6.75 Q3W
(N¼21)
6.75 Q4W
(N¼21)
10.0 Q4W
(N¼22)
Age (years)
Mean (s.d.) 53.2 (8.6) 69.7 (13.5) 70.2 (11.0) 74.0 (9.1) 68.8 (17.6) 64.0 (16.6) 70.5 (11.2) 68.8 (9.1)
Sex
(n/%) women 5 (83) 14 (42) 17 (52) 12 (40) 13 (59) 18 (86) 13 (62) 11 (50)
Disease (n/%)
Genitourinary 1 (17) 12 (36) 9 (27) 12 (40) 5 (23) 2 (10) 2 (10) 3 (14)
Breast 4 (67) 9 (27) 10 (30) 7 (23) 1 (5) 8 (38) 6 (29) 4 (18)
Lymphoid malignancy
a 0 (0) 6 (18) 8 (24) 3 (10) 4 (18) 5 (24) 6 (29) 1 (5)
Gastrointestinal 0 (0) 1 (3) 2 (6) 4 (13) 4 (18) 2 (10) 2 (10) 4 (18)
Lung 0 (0) 1 (3) 2 (6) 2 (7) 2 (9) 2 (10) 3 (14) 5 (23)
Gynaecologic 0 (0) 1 (3) 0 (0) 1 (3) 2 (9) 1 (5) 1 (5) 4 (18)
Other 1 (17) 3 (9) 2 (6) 1 (3) 4 (18) 1 (5) 1 (5) 1 (5)
Disease stage (n/%)
b
Stages I–II 0 (0) 11 (33) 4 (12) 7 (23) 6 (27) 4 (19) 6 (29) 5 (23)
Stages III–IV 6 (100) 21 (64) 27 (82) 21 (70) 15 (68) 15 (71) 12 (57) 15 (68)
Unknown 0 (0) 1 (3) 2 (6) 2 (7) 1 (5) 2 (10) 3 (14) 2 (9)
Pretreatment chemotherapy or radiotherapy (n/%) 5 (83) 27 (82) 28 (85) 23 (77) 18 (82) 17 (81) 17 (81) 21 (95)
Haemoglobin (gdl
 1)
Mean (s.d.) 9.60 (1.53) 9.80 (0.91) 9.62 (1.12) 10.05 (0.94) 9.84 (0.89) 9.84 (1.38) 10.20 (0.88) 10.10 (0.80)
Endogenous EPO (mU ml
 1)
N 6 3 3 3 3 2 8 2 12 02 12 1
Median 42.93 32.03 30.94 23.46 26.42 46.22 29.32 28.99
Q1, Q3 24.08, 159.41 21.25, 54.06 18.80, 99.55 16.07, 34.60 16.31, 38.43 20.61, 61.17 17.66, 47.78 16.41, 45.98
Ferritin (mgl
 1)
N 6 3 3 3 3 2 9 2 22 12 12 2
Median 1164.0 472.0 206.0 149.0 133.5 92.0 113.0 169.5
Q1, Q3 151.0, 2010.0 173.0, 942.0 97.0, 416.0 74.0, 402.0 36.0, 605.0 41.0, 292.0 50.0, 243.0 46.0, 465.0
aIncludes myelomas, chronic lymphocytic leukaemia, and non-Hodgkin’s lymphoma.
bDisease stage as defined by the investigator. QW¼once weekly; Q3W¼once every 3
weeks; Q4W¼once every 4 weeks; N¼number in cohort; s.d.¼standard deviation; n¼number in subset; EPO¼erythropoietin; Q¼quartile.
Table 2 Haemoglobin end points and red blood cell transfusions
Treatment group – placebo or darbepoetin alpha (lgkg
 1)
0.5 QW 1.0 QW 2.25 QW 4.5 QW Placebo 6.75 Q3W 6.75 Q4W 10.0 Q4W
(N¼6) (N¼33) (N¼33) (N¼30) (N¼22) (N¼21) (N¼21) (N¼22)
Haematopoietic response
Proportion
a 80 72 70 100 10 60 61 70
(95% CI) (45, 100) (55, 89) (53, 88) (100, 100) (0, 24) (36, 83) (39, 84) (50, 91)
Median time to haematopoietic response (days) 50 50 36 27 NE 57 36 40
Haemoglobin response
Proportion
a 80 69 67 92 5 58 49 60
(95% CI) (45, 100) (51, 87) (49, 85) (80, 100) (0, 15) (34, 82) (26, 73) (39, 82)
Mean change in haemoglobin concentration (gdl
 1) (imputed analysis)
b
Mean 1.45 1.66 2.07 2.91 0.00 1.18 1.22 1.70
95% CI ( 0.05,2.95) (0.90,2.42) (1.34,2.80) (2.20, 3.62) ( 0.39,0.39) (0.33,2.04) (0.53,1.92) (0.89,2.50)
Mean change in haemoglobin concentration (gdl
 1) (alternate analysis)
b
n 42 0 2 2 1 81 61 5 1 51 3
Mean 1.98 2.01 2.69 3.16 0.05 1.71 1.38 2.05
95% CI ( 0.8,4.75) (0.85,3.18) (1.83,3.55) (2.49,3.84) ( 0.40,0.50) (0.73,2.69) (0.48,2.28) (1.5,3.04)
Patients with RBC transfusion from week 5 to EOTP (subset analysis)
n 53 2 3 0 2 92 02 0 2 02 1
Proportion
a 20 36 14 7 21 16 6 10
(95% CI) (0, 55) (10, 62) (1, 26) (0, 17) (3, 39) (0, 33) (0, 16) (0, 23)
aProportion calculated using K-M estimate.
bChange from baseline calculated using last available haemoglobin value not within 28 days of a transfusion (imputed analysis), and for
patients with haemoglobin value at week 13 not within 28 days of a transfusion (alternate analysis). QW¼once weekly; Q3W¼once every 3 weeks; Q4W¼once every 4
weeks; N¼number in cohort; CI¼confidence interval; RBC¼red blood cell; EOTP¼end of treatment period; n¼number in subset; NE¼not estimable (median not
reached).
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Efficacy Incidence of patients achieving haematopoietic response:
With weekly dosing, the proportion of patients achieving
haematopoietic response ranged from 70% (95% CI¼53, 88) at
the 2.25mgkg
 1 dose to 100% (95% CI¼100, 100) at the
4.5mgkg
 1 dose (Table 2, Figure 2). In the Q3W/Q4W schedules,
the haematopoietic response ranged from 60% (95% CI¼36, 83) to
70% (95% CI¼50, 91) in the darbepoetin alpha cohorts and was
10% (95% CI¼0, 24) in the placebo cohort (Table 2, Figure 2).
Time to haematopoietic response: The QW data suggested a
dose–response relationship for time to haematopoietic response,
although none was apparent in the Q3W/Q4W schedules. The
median time to haematopoietic response was not reached in the
placebo group, and ranged from 27 to 57 days across the other
cohorts, with the 4.5mgkg
 1 QW cohort responding the fastest
(Table 2).
Incidence of patients achieving a haemoglobin response: In the
QW schedule, at least 67% of patients in each cohort achieved a
haemoglobin response, with the highest proportion of responders
(92%; 95% CI¼80, 100) at the 4.5mgkg
 1 dose (Table 2). In the
Q3W and Q4W schedules, the 6.75mgkg
 1 Q3W and 10.0mgkg
 1
Q4W groups had a similar proportion of responders (58% (95%
CI¼34, 82) and 60% (95% CI¼39, 82), respectively), with 49%
(95% CI¼26, 73) of patients in the 6.75mgkg
 1 Q4W group
responding. One patient who received placebo (5%; 95% CI¼0,
15) had a haemoglobin response.
Change in haemoglobin: In the QW schedule, a dose-response
relationship was suggested by the mean change in haemoglobin
concentration from baseline to the end of the treatment period,
with the greatest increase (2.91gdl
 1; 95% CI¼2.20, 3.62) at the
4.5mgkg
 1 dose (Table 2). In the Q3W and Q4W schedules, each
darbepoetin alpha cohort had a mean increase in haemoglobin
concentration of at least 1.0gdl
 1 during the 12 weeks of blinded
treatment, while mean haemoglobin concentration in the placebo
group was unchanged. When analysing only those patients who
completed at least 12 weeks of treatment (i.e., had a haemoglobin
value at week 13 with no transfusion during the preceding 28
days), the mean increases range from 1.98gdl
 1 (95% CI¼ 0.8,
4.75) to 3.16gdl
 1 (95% CI¼2.49, 3.84) with QW dosing, and
1.38gdl
 1 (95% CI¼0.48, 2.28) to 2.05gdl
 1 (95% CI¼1.5, 3.04)
with Q3W/Q4W dosing.
Patients who received darbepoetin alpha in the blinded phase
and then entered the open-label phase continued to receive
darbepoetin alpha at the same dose/schedule for 12 more weeks
while maintaining their haemoglobin concentration (Figure 3).
Patients who received placebo during the blinded phase of the
study and then crossed over to active treatment during the open-
label phase had an increase in haemoglobin concentration over
their 12 weeks of open-label darbepoetin alpha treatment, with
mean gains during these 12 weeks of 2.42gdl
 1 (95% CI¼ 0.12,
4.96) at 6.75mgkg
 1 Q3W, n¼5; 1.77gdl
 1 (95% CI¼ 0.13, 3.67)
at 6.75mgkg
 1 Q4W, n¼7; and 1.98gdl
 1 (95% CI¼0.51, 3.46 at
10.0mgkg
 1 Q4W, n¼6.
Red blood cell transfusions: While the eligibility criteria excluded
patients who were transfusion dependent, the incidence of
transfusions was assessed over the course of the study. A trend
towards fewer transfusions at the higher darbepoetin alpha dose
levels was apparent in the QW schedule (Table 2). In the Q3W/
Q4W schedules, 21% (95% CI¼3, 39) of patients receiving placebo
required a red blood cell transfusion, while the proportions for the
darbepoetin alpha cohorts ranged from 6% (95% CI¼0, 16) to
16% (95% CI¼0, 33).
HRQOL The FACT-Fatigue subscale had a mean baseline score of
26.9 (out of a possible maximum of 52 points) with a mean change
of 8.5 points (95% CI¼5.9, 11.1) for patients who had a X2gdl
 1
increase in haemoglobin compared to a 0.6-point decline (95% CI:
 6.0, 4.8) in patients with no increase in haemoglobin concen-
tration. Results from the composite scales all showed similar
trends with significant increases in scale score in patients with a
X2gdl
 1 increase in haemoglobin from baseline. The relationship
with increasing haemoglobin concentration was observed for the
FACT-Fatigue subscale (Jonckheere–Terpstra test P-value o0.01)
as well as other FACT-General subscales except for the FACT-
Social/Family well-being and FACT-Emotional subscales (Table 3).
As the FACT-Social/Family well-being subscale questions focus on
social support and family communication, this subscale was not
hypothesised to be correlated with either the symptoms of anaemia
or outcomes resulting from its treatment.
Pharmacokinetics As assessed in seven patients at the
6.75mgkg
 1 dose, serum concentrations of darbepoetin alpha
remained at effective levels for 2–3 weeks and returned to baseline
values within approximately 3 weeks. Key pharmacokinetic
parameters determined at this dose were mean area under the
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Figure 2 Proportion of patients with haematopoietic response.
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Figure 3 Mean change in haemoglobin over double-blind and open-
label phases of Q3W and Q4W schedules.
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lcurve (from time 0 to infinity) 3760nghml
 1, mean half-life
54.5h; and time to maximum concentration 47.9h.
Safety Safety was assessed by summarising the incidence of
adverse events by dose and treatment group. In general, the safety
profile of darbepoetin alpha was similar for all three schedules of
administration. The most frequently reported adverse events in the
QW schedule were fatigue (24%), arthralgia (19%), and asthenia
(19%). In the Q3W/Q4W schedules, the most frequent events were
fatigue (17% darbepoetin alpha; 27% placebo), dyspnoea (16%
darbepoetin alpha; 0% placebo), and nausea (16% darbepoetin
alpha; 18% placebo) (Figure 4).
No relation between dose and adverse events was noted.
Twenty-seven patients receiving darbepoetin alpha in the QW
schedule and eight in the blinded phase of the Q3W/Q4W
schedules reached the maximum haemoglobin concentration. Of
these, 26 patients had study drug withheld according to the
protocol; in general, haemoglobin concentrations decreased or
stabilised in these patients.
Twenty-four patients reached a haemoglobin concentration
413gdl
 1 accompanied by a X2.0gdl
 1 increase without previous
transfusion (12 patients in the QW schedule; seven darbepoetin
alpha patients and no placebo patients in the blinded portion of the
Q3W/Q4W schedules; five patients in the open-label portion). Too
few patients met this criterion to adequately evaluate potential
differences in the incidence and types of adverse events.
Four patients (3.9%) had thrombotic events during the QW
schedule (three with lower extremity deep vein thrombosis (DVT)
and one with a pulmonary embolism and a DVT). In the Q3W/
Q4W schedules, one placebo patient developed a bilateral lower
extremity DVT, and one patient in the open-label 10.0mgkg
 1
Q4W group developed a left lower extremity DVT and bilateral
pulmonary emboli. None of these events were associated with a
rapid increase in haemoglobin (as defined in the previous
paragraph) or a protocol-specified maximum haemoglobin level
(414.0gdl
 1 for women, 415.0gdl
 1 for men).
No evidence of neutralising antibodies to darbepoetin alpha was
detected.
DISCUSSION
This was the first dose-finding study of an erythropoietic agent in
patients with anaemia of cancer not concurrently being treated
with chemotherapy. Eighty-three percent of the patients had
received prior chemotherapy or radiotherapy; of these, 72% had
received their last chemotherapy at least 25 weeks previously, and
none more recently than 8 weeks previously, indicating that this
was truly a population with anaemia of chronic disease rather than
one experiencing the residual effects of recent chemotherapy. As
would be expected in anaemia of chronic disease, laboratory
indices indicated suppression of endogenous EPO and evidence of
impaired iron utilisation. Although patients in the QW and Q3W/
Q4W schedules were not enrolled contemporaneously, they can
legitimately be compared because the same population of patients
was studied and the study designs were similar. Few conclusions
can be drawn about the 0.5mgkg
 1 cohort because of its small
sample size (n¼6), and this dose is disregarded for the remainder
of the discussion – although it is interesting that 80% of patients
even at this low dose achieved a haemoglobin response.
Adverse events observed in this study were consistent with those
expected for an elderly population of patients with cancer and
chronic anaemia and were similar for all doses and schedules. The
16% incidence of dyspnoea in the Q3W/Q4W schedules is similar
to that seen in the QW schedule (13%); the discrepancy with the
placebo group may be an artefact of the small sample sizes, as
Table 3 Change in FACT scales with change in haemoglobin concentration (QW, Q2W, and Q3W schedules combined)
Haemoglobin change category (baseline to end of treatment period)
Baseline value <0gdl
 1 0g/dL–<2gdl
 1 X2gdl
 1
FACT scales n, Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
n 183
a 22 76
b 85
c
FACT Fatigue subscale 26.9 (25.0, 28.8)  0.6 ( 6.0, 4.8) 1.7 ( 1.1, 4.5) 8.5 (5.9, 11.1)
FACT Anaemia symptoms subscale 17.8 (17.0, 18.5)  1.4 ( 4.3, 1.5) 0.8 (0.0, 1.6) 2.5 (1.5, 3.5)
FACT Anaemia subscale score
d 44.6 (42.2, 47.1)  2.0 ( 9.7, 5.7) 2.5 ( 0.8, 5.9) 11.0 (7.8, 14.2)
FACT-G Physical well-being subscale 19.3 (18.4, 20.1)  1.2 ( 3.5, 1.1) 0.4 ( 0.9, 1.6) 2.8 (1.6, 4.0)
FACT-G Social/Family well-being subscale 21.6 (20.7, 22.5)  0.4 ( 2.9, 2.0)  0.2 ( 1.6, 1.1)  0.4 ( 1.4, 0.6)
FACT-G Emotional well-being subscale 17.5 (16.8, 18.3)  0.2 ( 2.3, 2.0) 0.8 ( 0.1, 1.7) 1.5 (0.7, 2.3)
FACT-G Functional well-being subscale 14.6 (13.6, 15.6)  2.1 ( 4.6, 0.4) 0.0 ( 1.3, 1.3) 3.6 (2.4, 4.9)
FACT-G Overall scale
e 73.0 (70.4, 75.6)  3.9 ( 9.7, 2.0) 1.2 ( 1.9, 4.3) 7.6 (4.6, 10.6)
FACT Anaemia total scale
f 117.5 (112.7, 122.2)  5.9 ( 18.6, 6.9) 4.1 ( 1.6, 9.8) 18.7 (12.9, 24.6)
an¼182 for the FACT-G Functional scale, 179 for the Social/Family scale, and 178 for the Overall and Anaemia Total scales.
bn¼73 for the FACT-G Social/Family, Overall, and
Anaemia Total scales.
cn¼84 for the FACT-G Social/Family and Functional scales and 83 for the Overall and Anaemia total scales.
dAnaemia subscale score¼Fatigue+Anaemia
symptoms.
eFACT-G Overall score¼Physical well-being+Social/family well-being+Emotional well-being+Functional well-being.
fFACT Anaemia total score¼FACT-G+Anaemia
subscale score.
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Figure 4 Adverse events that occurred with X15% incidence in either
treatment group in the Q3W and Q4W schedules.
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ldyspnoea would be expected to be relatively common in anaemic
patients.
A robust response in haemoglobin levels was seen at all doses/
schedules, whether QW, Q3W, or Q4W, with at least 60% of all
cohorts achieving an increase of X2gdl
 1 and/or a concentration
X12gdl
 1 in the absence of transfusions. Using the standard
measures of efficacy, the QW dose cohorts (1.0–4.5mgkg
 1
darbepoetin alpha QW) achieved response rates that were generally
higher than those previously reported with rHuEPO. Haemoglobin
response rates ranged from approximately 70 to 90% of patients,
compared with 48% (39% of whom required a doubling of dose at
week 5) in the recently reported study by Quirt et al (2001). A
trend towards decreasing time to response with increasing dose
was also observed with the QW schedule of administration for
darbepoetin alpha. Mean haemoglobin concentration increased by
1.45gdl
 1 (95% CI¼ 0.05, 2.95) to 2.91g dl
 1 (95% CI¼2.20,
3.62) across the various cohorts. For those patients who completed
12 weeks of treatment, the mean increase was generally 0.2–
0.5gdl
 1 higher than the values obtained using the analysis that
includes the last observed value for patients who withdrew from
the study early.
Darbepoetin alpha was also shown to be effective when
administered every 3 or 4 weeks compared with placebo.
Haemoglobin response rates of approximately 50% or greater
were observed despite the infrequent schedule, with haematopoie-
tic response rates of between 60 and 70% with Q3W or Q4W
administration. An evaluation of the efficiency of darbepoetin
alpha as the schedule of administration decreases is possible in this
study. At dose/schedules that administered an approximately
equivalent cumulative dose of darbepoetin alpha, the impact on
haemoglobin variables was broadly similar, for example, haema-
topoietic response was achieved by 70% (95% CI¼53, 88) of
patients at 2.25mgkg
 1 QW; by 60% (95% CI¼36, 83) at
6.75mgkg
 1 Q3W; and by 70% (95% CI¼50, 91) at 10mgkg
 1
Q4W. Although the study was not designed to test individual doses
against placebo, based on the (family-wise) 95% CI, a higher
proportion of patients receiving darbepoetin alpha 6.75mgkg
 1
Q4W (the lowest dose in the placebo-controlled portion of the
study) met the criteria for haemoglobin and haematopoietic
response than placebo patients, suggesting that this may be an
effective monthly dose.
The mean haemoglobin increases for the placebo cohorts
crossing over to darbepoetin alpha during the second 12 weeks
were somewhat greater than those for the darbepoetin alpha
groups during the first 12 weeks; this is probably the result of
selection bias as the more debilitated patients withdrew from the
study. That placebo patients had no increase in haemoglobin
during the first 12 weeks provides additional evidence that this
population was genuinely anaemic because of the anaemia of
chronic disease and not just recovering from prior chemotherapy.
This study was not designed to conclusively evaluate the effect
on transfusions, as it had a relatively small sample size to evaluate
infrequently occurring events. The eligibility criteria minimised
the entry of patients with any significant transfusion requirement,
probably reducing the number of transfusions over the course of
the 12-week study period as well, and consequently minimising
differences between the placebo and treatment groups. The
transfusion rates in the darbepoetin alpha groups are generally
similar to those reported in the literature for patients treated with
rHuEPO (Glaspy et al, 1997; Demetri et al, 1998; Littlewood et al,
2001; Quirt et al, 2001).
Similarly, because of the exploratory nature of this study,
conclusive evidence regarding HRQOL cannot be provided.
However, the relation between FACT-F scores, particularly the
reduction in fatigue, and haemoglobin concentration seen here is
consistent with other reports that have found improved alleviation
of patient-reported symptoms of anaemia with increasing haemo-
globin levels (Glaspy et al, 1997; Gabrilove et al, 2001).
Confirmatory studies are needed to investigate whether the
observed increases in haemoglobin translate into reductions in
transfusion requirements and/or improvements in HRQOL.
Frequent dosing with rHuEPO may be particularly inconvenient
for anaemic cancer patients who are not receiving chemotherapy,
as it may create the need for clinic visits that would otherwise not
be necessary, and introduces a burdensome regimen for those
living with a potentially long-term condition. A direct comparison
of rHuEPO and darbepoetin alpha would be of interest to better
understand the relative advantages of less-frequent dosing and the
comparative efficacy of the two agents. The findings from this
phase 2 study have shown that darbepoetin alpha is effective
compared with placebo using administration schedules as
infrequent as every 4 weeks. Weekly administration of darbepoetin
alpha resulted in up to 100% of patients achieving a response, and
observed rates of response using Q3W and Q4W schedules were at
least comparable to those seen with three-times-weekly rHuEPO in
this population (Abels et al, 1991; Quirt et al, 2001). Based on the
evidence from this study, even the lowest dose of darbepoetin
alpha (6.75mgkg
 1) administered Q4W demonstrated superior
haematologic responses (e.g., change in haemoglobin, haemoglo-
bin response) compared with placebo. In summary, darbepoetin
alpha appears to be a potent agent for increasing haemoglobin
concentration in anaemic patients with cancer not receiving
chemotherapy, allowing almost all patients to achieve desired
concentrations; less frequent administration provides significant
benefits to patients, their caregivers, and the oncology office
practice.
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APPENDIX 1.
Additional members (investigators) of the Aranesp 990111 Study
Group
Mark J Adler (Oncology Medical Center of North County,
Vista, CA, USA); Heather J Allen (Southwest Cancer Clinic - East
Office, Las Vegas, NV, USA); John Barstis (UCLA/Antelope Valley
Cancer Center, Lancaster, CA, USA); Barry Berman (Cancer
Center of Florida, FL, USA); Douglas W Blayney (The Robert &
Beverly Lewis Family Cancer Care Center, Pomona, CA, USA);
Stanley A Brosman (Pacific Clinical Research, Santa Monica,
CA, USA); Robert P Brouillard (La Jolla, CA, USA); Ronald
Bukowski (Cleveland Clinic Foundation, Cleveland, OH, USA);
Patrick J Cannon (Encino, CA, USA); Joseph F Chang (Bakersfield,
CA, USA); Harry Griffith (Western Washington Oncology,
Shelton, WA, USA); Julie Hersch (Santa Cruz, CA, USA); Ishmael
Jaiyesimi (Beaumont Cancer Center, Royal Oak, MI, USA); Glen
Justice (Pacific Coast Hematology Oncology Medical Group,
Fountain Valley, CA, USA); Jay P Klarnet (Hematology Oncology
Northwest, Tacoma, WA, USA); Richard Lloyd (Virginia K.
Crosson Cancer Center, Fullerton, CA, USA); Rosemary E
McIntyre (Ventura County Hematology Oncology Specialists,
Oxnard, CA, USA); Harry Menco (Thousand Oaks, CA, USA);
Myron Murdock (Drs Wemer, Murdock, Francis, PA, Urology
Associates, Greenbelt, MD, USA); Christopher Perkins (California
Oncology of the Central Valley, Fresno, CA, USA); James E Pero
(Thousand Oaks, CA, USA); James L Pot (Santa Cruz, CA, USA);
Mark Rarick (Hematology/Oncology, Kaiser Permanente,
Portland, OR, USA); Donald Richards (Tyler Cancer Center,
Tyler, TX, USA); Alan Saven (Scripps Clinic, Division of
Hematology Oncology, La Jolla, CA, USA); Roger Shiffman
(Monterey Bay Oncology, Monterey, CA, USA); and Thomas
Woliver (Santa Barbara Hematology Oncology Medical Group, Inc,
CA, USA).
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